NCT05187026
Unknown
Not Applicable
Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy
ConditionsProstate Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Helsinki University Central Hospital
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- preference
- Last Updated
- 4 years ago
Overview
Brief Summary
This is an observational study where prostate cancer related PROMs (EPIC-26) is collected using two different methods (by paper questionnaires and electronically) and patient experience and preference is asked.
Detailed Description
Prostate cancer patients that are treated with radiation therapy for local prostate cancer receive EPIC-26 before treatment and during follow-up. EPIC-26 is collected both traditionally using paper questionnaires and electronically. Patients experience and preference for these are asked.
Investigators
Antti Rannikko
assistant professor
Helsinki University Central Hospital
Eligibility Criteria
Inclusion Criteria
- •cT1-4N0M0, gleason 6-10, PSA \< 100, WHO ≤ 2 prostate cancer eligible for radiation therapy
- •willing to complete EPIC-26 questionnaires both in paper and electronically
- •willing to consent for the study
Exclusion Criteria
- •not able to complete EPIC-26 both in paper and electronically
Outcomes
Primary Outcomes
preference
Time Frame: through study completion, an average of 1 year
patient preference for type of questionnaire (paper versus electronic)
Secondary Outcomes
- QoL as measured using the validated EPIC-26 questionnaire(through study completion, an average of 1 year)
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Prostate Cancer BiobankProstatic NeoplasmsNCT04024475Swiss Group for Clinical Cancer Research1,323
Unknown
Phase 1
MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound GuidanceProstatic NeoplasmsNCT02233725University of British Columbia50
Recruiting
Not Applicable
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate CancerProstatic NeoplasmNCT06236789Yonsei University60
Withdrawn
Not Applicable
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityProstate CancerNCT04580667DiaCarta, Inc.250
Withdrawn
Not Applicable
Prostate Cancer Parameters for Patients Receiving Proton TreatmentProstate CancerNCT02110849Indiana University